CCDC Weekly – Weekly Reports: Current Volume (3)
2021-05-21 / No. 21
PDF of this issue
:: Outbreak Reports: COVID-19 Outbreak Caused by Contaminated Packaging of Imported Cold-Chain Products — Liaoning Province, China, July 2020
:: Methods and Applications: Development of a PDRA Method for Detection of the D614G Mutation in COVID-19 Virus — Worldwide, 2021
:: Notes from the Field: The First Reported Case of COVID-19 and Plasmodium ovale Malaria Coinfection — Guangdong Province, China, January 2021
:: Notes from the Field: Two Imported Cases of New Variant COVID-19 First Emerging from Brazil — Guangdong Province, China, April 30, 2021
:: Recommendations: Technical Vaccination Recommendations for COVID-19 Vaccines in China (First Edition)
To date, five coronavirus disease 2019 (COVID-19) vaccines have been conditionally approved for market authorization or granted emergency use authorization in China by the National Medical Products Administration (NMPA). Three inactivated COVID-19 vaccines and one adenovirus-vectored vaccine were granted conditional approval, as phase Ⅲ clinical trial data for these four conditionally-approved vaccines have demonstrated protective efficacy levels that meet requirements of NMPA’s Guidelines for Clinical Evaluation of COVID-19 vaccine (interim version) and also meet requirements recommended by the World Health Organization (WHO) in their COVID-19 Vaccines Target Product Profile. Adverse event surveillance data from clinical trials, emergency use, and large-scale vaccination of key populations have demonstrated that the approved COVID-19 vaccines have excellent safety profiles. One recombinant subunit COVID-19 vaccine was approved for emergency use, as phase Ⅱ clinical trial results showed good immunogenicity and safety of the recombinant subunit COVID-19 vaccine (CHO cell).
Based on clinical trial data of the NMPA-approved domestic vaccines and the epidemiological characteristics of COVID-19, the COVID-19 Vaccine Technical Working Group of China CDC drafted technical vaccination recommendations. The National Immunization Advisory Committee reviewed, discussed, and refined the recommendations. The National Health Commission accepted and published these recommendations (1)…
National Health Commission of the People’s Republic of China [to 22 May 2021]
May 22: Daily briefing on novel coronavirus cases in China
On May 21, 31 provincial-level regions and the Xinjiang Production and Construction Corps on the Chinese mainland reported 10 new cases of confirmed infections.
Single-dose vaccine now available
Several cities across China have recently started offering residents a single-dose COVID-19 vaccine in addition to the two-dose inactivated vaccines that were already widely used in the country’s vaccination drive.
At the temporary vaccination station in Shanghai’s Xuhui district on Wednesday, a new CanSino sign was placed alongside the Sinovac and Sinopharm ones as vaccine providers of the day…
National Medical Products Administration – PRC [to 22 May 2021]
Over 449m doses of COVID-19 vaccines administered in China
More than 449.5 million doses of COVID-19 vaccines had been administered in China as of May 19, the National Health Commission said on May 20.